0001104659-23-040289.txt : 20230331 0001104659-23-040289.hdr.sgml : 20230331 20230331170659 ACCESSION NUMBER: 0001104659-23-040289 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230330 FILED AS OF DATE: 20230331 DATE AS OF CHANGE: 20230331 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Golembiewski Michael Joseph CENTRAL INDEX KEY: 0001639479 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22245 FILM NUMBER: 23789030 MAIL ADDRESS: STREET 1: 7 TURTLE CT CITY: FLEMINGTON STATE: NJ ZIP: 08822 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001017491 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870449967 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646) 293-2100 MAIL ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC. DATE OF NAME CHANGE: 20100914 FORMER COMPANY: FORMER CONFORMED NAME: NEXMED INC DATE OF NAME CHANGE: 19970311 4 1 tm2311208-1_4seq1.xml OWNERSHIP DOCUMENT X0407 4 2023-03-30 0 0001017491 SEELOS THERAPEUTICS, INC. SEEL 0001639479 Golembiewski Michael Joseph C/O SEELOS THERAPEUTICS, INC. 300 PARK AVENUE, 2ND FLOOR NEW YORK NY 10022 0 1 0 0 Chief Financial Officer 0 Stock Option (right to buy) 0.69 2023-03-30 4 A 0 677701 0.00 A 2033-03-30 Common Stock 677701 677701 D Stock Option (right to buy) 0.69 2023-03-30 4 A 0 88030 0.00 A 2023-03-30 2033-03-30 Common Stock 88030 88030 D 1/4th of the shares subject to the option shall vest on March 30, 2024, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Reporting Person's continued service to the Issuer through such vesting date. The Reporting Person voluntarily elected to be paid 35% of his 2022 annual cash bonus in the form of an option to purchase shares of common stock of the Issuer. /s/ Michael Golembiewski 2023-03-31